O'Sullivan, Ciara C <br/><br/>
Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.  [electronic resource] 

 -  Oncology (Williston Park, N.Y.)  Mar 2014 
 - 186-94, 196 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>0890-9091 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal, Humanized--pharmacokinetics<br/>Antineoplastic Agents--pharmacokinetics<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant<br/>Drug Approval<br/>Female<br/>Humans<br/>Molecular Targeted Therapy<br/>Neoadjuvant Therapy<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Signal Transduction--drug effects<br/>Time Factors<br/>Treatment Outcome<br/>United States<br/>United States Food and Drug Administration